SPARC licenses development and commercialisation rights of PDP-716 and SDN-037 to Visiox Pharma
SPARC to receive equity in Visiox along with other financial considerations
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
PDP-716
SPARC declares positive results from Phase 3 clinical trial of PDP-716 to treat open-angle glaucoma…
The primary endpoint of the trial was to evaluate the efficacy of once daily (QD) dosing of PDP-716 0.35 per cent compared with…